Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Largest borrow rate increases among liquid names » 08:45
02/01/23
02/01
08:45
02/01/23
08:45
XM

Qualtrics

$15.75 /

+0.01 (+0.06%)

, GDS

GDS Holdings

$23.35 /

-0.4 (-1.68%)

, LIT

Litton Ind

$70.70 /

+0.43 (+0.61%)

, QS

QuantumScape

$8.52 /

+0.48 (+5.97%)

, CVNA

Carvana

$10.16 /

+0.13 (+1.30%)

, FRO

Frontline

$13.83 /

+0.215 (+1.58%)

, EWI

MSCI Italy Index

$30.25 /

+0.55 (+1.85%)

, RUM

Rumble

$10.04 /

+0.04 (+0.40%)

, ACB

Aurora Cannabis

$1.03 /

+0.0579 (+5.96%)

Latest data shows the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XM Qualtrics
$15.75 /

+0.01 (+0.06%)

RUM Rumble
$10.04 /

+0.04 (+0.40%)

QS QuantumScape
$8.52 /

+0.48 (+5.97%)

FRO Frontline
$13.83 /

+0.215 (+1.58%)

CVNA Carvana
$10.16 /

+0.13 (+1.30%)

ACB Aurora Cannabis
$1.03 /

+0.0579 (+5.96%)

XM Qualtrics
$15.75 /

+0.01 (+0.06%)

01/27/23 BMO Capital
SAP price target raised to $125 from $110 at BMO Capital
01/27/23 BMO Capital
Qualtrics price target raised to $17 from $13 at BMO Capital
01/27/23 Barclays
Qualtrics price target raised to $15 from $11 at Barclays
01/26/23 Oppenheimer
Qualtrics price target raised to $17 from $14 at Oppenheimer
GDS GDS Holdings
$23.35 /

-0.4 (-1.68%)

11/29/22 RBC Capital
GDS Holdings price target lowered to $15 from $22 at RBC Capital
11/23/22 Truist
GDS Holdings price target lowered to $50 from $75 at Truist
11/23/22 HSBC
GDS Holdings price target lowered to $36 from $39 at HSBC
08/26/22 RBC Capital
GDS Holdings downgraded to Sector Perform from Outperform at RBC Capital
LIT Litton Ind
$70.70 /

+0.43 (+0.61%)

QS QuantumScape
$8.52 /

+0.48 (+5.97%)

01/25/23 Morgan Stanley
QuantumScape price target lowered to $3 from $4 at Morgan Stanley
12/13/22 Goldman Sachs
QuantumScape downgraded to Sell from Neutral at Goldman Sachs
11/09/22 Morgan Stanley
Morgan Stanley cuts QuantumScape to Underweight after 'narrative changing' Q3
11/09/22 Morgan Stanley
QuantumScape downgraded to Underweight from Equal Weight at Morgan Stanley
CVNA Carvana
$10.16 /

+0.13 (+1.30%)

01/26/23 JMP Securities
Carvana price target lowered to $15 from $25 at JMP Securities
01/17/23 Raymond James
Carvana poison pill suggests board's defensive stance, says Raymond James
01/05/23 Wells Fargo
Carvana price target lowered to $5 from $25 at Wells Fargo
12/28/22 Wedbush
Wedbush reiterates Underperform on Carvana on weakening results, liquidity
FRO Frontline
$13.83 /

+0.215 (+1.58%)

01/12/23 Deutsche Bank
Frontline price target raised to $16.50 from $15 at Deutsche Bank
01/11/23 JonesResearch
Euronav NV upgraded to Buy from Hold at JonesResearch
01/10/23 Stifel
Euronav NV downgraded to Hold from Buy at Stifel
11/29/22 Jefferies
Frontline price target raised to $17 from $16 at Jefferies
EWI MSCI Italy Index
$30.25 /

+0.55 (+1.85%)

RUM Rumble
$10.04 /

+0.04 (+0.40%)

12/02/22 Oppenheimer
Rumble initiated with a Perform at Oppenheimer
ACB Aurora Cannabis
$1.03 /

+0.0579 (+5.96%)

01/27/23 Stifel
Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel
12/28/22 Piper Sandler
Aurora Cannabis price target lowered to $1 from $2 at Piper Sandler
11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
XM Qualtrics
$15.75 /

+0.01 (+0.06%)

QS QuantumScape
$8.52 /

+0.48 (+5.97%)

GDS GDS Holdings
$23.35 /

-0.4 (-1.68%)

FRO Frontline
$13.83 /

+0.215 (+1.58%)

CVNA Carvana
$10.16 /

+0.13 (+1.30%)

ACB Aurora Cannabis
$1.03 /

+0.0579 (+5.96%)

  • 27
    May
  • 22
    Apr
RUM Rumble
$10.04 /

+0.04 (+0.40%)

CVNA Carvana
$10.16 /

+0.13 (+1.30%)

ACB Aurora Cannabis
$1.03 /

+0.0579 (+5.96%)

XM Qualtrics
$15.75 /

+0.01 (+0.06%)

RUM Rumble
$10.04 /

+0.04 (+0.40%)

QS QuantumScape
$8.52 /

+0.48 (+5.97%)

GDS GDS Holdings
$23.35 /

-0.4 (-1.68%)

FRO Frontline
$13.83 /

+0.215 (+1.58%)

CVNA Carvana
$10.16 /

+0.13 (+1.30%)

ACB Aurora Cannabis
$1.03 /

+0.0579 (+5.96%)

XM Qualtrics
$15.75 /

+0.01 (+0.06%)

RUM Rumble
$10.04 /

+0.04 (+0.40%)

QS QuantumScape
$8.52 /

+0.48 (+5.97%)

LIT Litton Ind
$70.70 /

+0.43 (+0.61%)

GDS GDS Holdings
$23.35 /

-0.4 (-1.68%)

FRO Frontline
$13.83 /

+0.215 (+1.58%)

EWI MSCI Italy Index
$30.25 /

+0.55 (+1.85%)

CVNA Carvana
$10.16 /

+0.13 (+1.30%)

ACB Aurora Cannabis
$1.03 /

+0.0579 (+5.96%)

Hot Stocks
InterCure terminates acquisition agreement with Cann Pharmaceutical » 08:33
02/01/23
02/01
08:33
02/01/23
08:33
INCR

InterCure

$3.70 /

+0.11 (+3.06%)

InterCure announces that,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INCR InterCure
$3.70 /

+0.11 (+3.06%)

INCR InterCure
$3.70 /

+0.11 (+3.06%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
INCR InterCure
$3.70 /

+0.11 (+3.06%)

INCR InterCure
$3.70 /

+0.11 (+3.06%)

INCR InterCure
$3.70 /

+0.11 (+3.06%)

Monday
Hot Stocks
TerrAscend closes on acquisition of Allegany Medical Marijuana Dispensary » 09:59
01/30/23
01/30
09:59
01/30/23
09:59
TRSSF

TerrAscend

$1.25 /

+0.04 (+3.31%)

TerrAscend announced the…

TerrAscend announced the closing of its previously announced acquisition of Allegany Medical Marijuana Dispensary, a medical dispensary in Cumberland, Maryland. Under the terms of the agreement, TerrAscend has acquired a 100% equity interest in AMMD for total consideration of $10M in cash, in addition to entering into a long-term lease with the option to purchase the real estate. This medical dispensary, located in Northwest Maryland within six miles of both the West Virginia and Pennsylvania borders, generated net revenues in excess of $8M in 2022. In anticipation of adult use later this year, TerrAscend expects to rebrand the 10,000 square foot dispensary as The Apothecarium, the Company's award-winning retail dispensary concept. The dispensary will carry TerrAscend's full selection of high-quality branded products, including Gage, Kind Tree, Valhalla, and Wana edibles, subject to regulatory approval. TerrAscend's retail footprint now includes 32 dispensaries nationwide.

ShowHide Related Items >><<
TRSSF TerrAscend
$1.25 /

+0.04 (+3.31%)

TRSSF TerrAscend
$1.25 /

+0.04 (+3.31%)

10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
09/12/22 Canaccord
TerrAscend initiated with a Buy at Canaccord
08/15/22 Cowen
TerrAscend price target lowered to $4.50 from $9 at Cowen
08/12/22 Stifel
TerrAscend price target lowered to C$5.50 from C$6 at Stifel
Downgrade
Ayr Wellness downgraded to Speculative Buy from Buy at Canaccord » 07:23
01/30/23
01/30
07:23
01/30/23
07:23
AYRWF

Ayr Wellness

$1.29 /

+0.05 (+4.03%)

Canaccord analyst Matt…

Canaccord analyst Matt Bottomley downgraded Ayr Wellness to Speculative Buy from Buy with a price target of C$16.50, down from C$21, after the company announced it has terminated its previously disclosed planned acquisition of Gentle Ventures, or "Dispensary 33," an Illinois-based cannabis operator with two retail dispensaries in the Chicago area. Though the firm views the announcement as incrementally positive in the near-term, it has lowered its estimated long-term contribution from state as a result. However, Canaccord noted that its lower recommendation is not a function of the deal headline, but rather increased concerns over the ability for the company to manage its debt load and the fact that its thinks "the prospect for a material valuation re-rating more speculative in nature" with Ayr's share price down more than 60% since November of last year.

ShowHide Related Items >><<
AYRWF Ayr Wellness
$1.29 /

+0.05 (+4.03%)

AYRWF Ayr Wellness
$1.29 /

+0.05 (+4.03%)

10/28/22 BTIG
Ayr Wellness initiated with a Buy at BTIG
08/19/22 Canaccord
Ayr Wellness price target lowered to C$30 from C$40 at Canaccord
08/19/22 Northland
Ayr Wellness price target lowered to $10 from $14 at Northland
08/19/22 Canaccord
Ayr Wellness price target lowered to C$30 from C$40 at Canaccord
AYRWF Ayr Wellness
$1.29 /

+0.05 (+4.03%)

AYRWF Ayr Wellness
$1.29 /

+0.05 (+4.03%)

Friday
Hot Stocks
Charlotte's Web 'encouraged' after FDA statement, agrees on testing's importance » 14:49
01/27/23
01/27
14:49
01/27/23
14:49
CWBHF

Charlotte's Web

/

+

Charlotte's Web…

Charlotte's Web issued the following statement regarding the FDA's January 26th press announcement: "Charlotte's Web is encouraged that the Administration has agreed that it is necessary for Congress to act for the regulation of hemp-derived cannabidiol, or 'CBD.' The FDA position has taken four years to come together, while the CBD industry has matured without a clear regulatory pathway for CBD products that are already available for sale in all 50 states and consumed safely by millions of Americans. This includes professional athletes, veterans, and everyday wellness seekers. The company looks forward to continuing its work in Washington DC to forward this process. The company also agrees with the FDA on the importance of testing to ensure the quality and safety of CBD products and has already provided studies to support this position. As the CBD pioneer and market leader, Charlotte's Web has engaged in safety studies and compiled toxicology data including liver safety. These studies have been conducted under an Institutional Review Board and Good Laboratory Practices, following guidelines of the Organization for Economic Co-operation and Development. They have been subjected to an unbiased peer review and published in journals and have been vetted and accepted for indexing in the PubMed central database. These studies support the efforts of a legislative regulatory framework. During this four-year period of regulatory absence, Charlotte's Web has set the standard in responsible self-regulation in product manufacturing, safety, and labeling. In addition to safety and toxicology studies the Company utilizes cGMP-compliant manufacturing facilities, seed-to-shelf testing, and certificate of analysis transparency for all products. Recently, Charlotte's Web became the first and only broad-spectrum CBD hemp extract to be NSF Certified for Sport, the gold standard to ensure safe and consistent products for professional athletes and consumers alike."

ShowHide Related Items >><<
CWBHF Charlotte's Web
/

+

CWBHF Charlotte's Web
/

+

08/10/22 Canaccord
Charlotte's Web price target lowered to C$2 from C$2.25 at Canaccord
05/20/22 Cowen
Charlotte's Web price target lowered to $1 from $2 at Cowen
05/18/22 Canaccord
Charlotte's Web price target lowered to C$2.25 from C$3 at Canaccord
05/18/22 Benchmark
Charlotte's Web downgraded to Hold from Speculative Buy at Benchmark
Recommendations
Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel » 11:06
01/27/23
01/27
11:06
01/27/23
11:06
ACB

Aurora Cannabis

/

+

Stifel analyst W. Andrew…

Stifel analyst W. Andrew Carter lowered the firm's price target on Aurora Cannabis to C$1.45 from C$1.75 and keeps a Hold rating on the shares.

ShowHide Related Items >><<
ACB Aurora Cannabis
/

+

ACB Aurora Cannabis
/

+

12/28/22 Piper Sandler
Aurora Cannabis price target lowered to $1 from $2 at Piper Sandler
11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
09/21/22 Canaccord
Aurora Cannabis upgraded to Hold from Sell at Canaccord
ACB Aurora Cannabis
/

+

  • 27
    May
ACB Aurora Cannabis
/

+

ACB Aurora Cannabis
/

+

ACB Aurora Cannabis
/

+

Hot Stocks
Ayr Wellness announces mutual termination of Dispensary 33 acquistion » 08:15
01/27/23
01/27
08:15
01/27/23
08:15
AYRWF

Ayr Wellness

$1.24 /

-0.05 (-3.88%)

Ayr Wellness announced…

Ayr Wellness announced the termination of the Company's previously announced proposed acquisition of the equity interests of Gentle Ventures, LLC d/b/a Dispensary 33, and certain of its affiliates that collectively own and operate two licensed retail dispensaries in Chicago, Illinois. Following the mutual termination, Ayr will no longer be required to pay the previously announced purchase consideration of $55M upfront, including $12M of cash, $3M of sellers notes and $40M of stock.

ShowHide Related Items >><<
AYRWF Ayr Wellness
$1.24 /

-0.05 (-3.88%)

AYRWF Ayr Wellness
$1.24 /

-0.05 (-3.88%)

10/28/22 BTIG
Ayr Wellness initiated with a Buy at BTIG
08/19/22 Canaccord
Ayr Wellness price target lowered to C$30 from C$40 at Canaccord
08/19/22 Northland
Ayr Wellness price target lowered to $10 from $14 at Northland
08/19/22 Canaccord
Ayr Wellness price target lowered to C$30 from C$40 at Canaccord
AYRWF Ayr Wellness
$1.24 /

-0.05 (-3.88%)

AYRWF Ayr Wellness
$1.24 /

-0.05 (-3.88%)

Thursday
On The Fly
Here's What You Missed in Cannabis, Psychedelics This Week » 11:38
01/26/23
01/26
11:38
01/26/23
11:38
AVTBF

Avant Brands

/

+

, BMMJ

Body and Mind

/

+

, LOVFF

Cannara Biotech

/

+

, CLVR

Clever Leaves

/

+

, CURLF

Curaleaf

$3.61 /

-0.2276 (-5.93%)

, DMTTF

Small Pharma

/

+

, IIPR

Innovative Industrial Properties

$85.74 /

-0.64 (-0.74%)

, ACB

Aurora Cannabis

/

+

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$2.72 /

-0.045 (-1.63%)

, CRON

Cronos Group

$2.41 /

-0.04 (-1.63%)

, GDNSF

Goodness Growth

/

+

, GTBIF

Green Thumb Industries

$7.81 /

-0.08 (-1.01%)

, TLRY

Tilray

$3.04 /

-0.055 (-1.78%)

, CANN

Trees Corporation

/

+

, TCNNF

Trulieve Cannabis

$6.31 /

-0.35 (-5.26%)

, ZYNE

Zynerba

/

+

, ATAI

Atai Life Sciences

$1.85 /

-0.015 (-0.80%)

, RLMD

Relmada Therapeutics

$4.31 /

-0.06 (-1.37%)

, CMPS

Compass Pathways

$10.73 /

+0.12 (+1.13%)

, IGC

India Globalization Capital

/

+

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$3.04 /

-0.055 (-1.78%)

TCNNF Trulieve Cannabis
$6.31 /

-0.35 (-5.26%)

RLMD Relmada Therapeutics
$4.31 /

-0.06 (-1.37%)

IIPR Innovative Industrial Properties
$85.74 /

-0.64 (-0.74%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$7.81 /

-0.08 (-1.01%)

GDNSF Goodness Growth
/

+

DMTTF Small Pharma
/

+

CVSI CV Sciences
/

+

CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

CRON Cronos Group
$2.41 /

-0.04 (-1.63%)

CMPS Compass Pathways
$10.73 /

+0.12 (+1.13%)

CLVR Clever Leaves
/

+

CGC Canopy Growth
$2.72 /

-0.045 (-1.63%)

CANN Trees Corporation
/

+

AVTBF Avant Brands
/

+

ATAI Atai Life Sciences
$1.85 /

-0.015 (-0.80%)

ACB Aurora Cannabis
/

+

AVTBF Avant Brands
/

+

BMMJ Body and Mind
/

+

LOVFF Cannara Biotech
/

+

CLVR Clever Leaves
/

+

11/11/22 Canaccord
Clever Leaves downgraded to Hold at Canaccord on slow growth
11/11/22 Canaccord
Clever Leaves downgraded to Hold from Buy at Canaccord
08/01/22 Cantor Fitzgerald
Cantor starts Clever Leaves at Overweight for overseas medical cannabis exposure
08/01/22 Cantor Fitzgerald
Clever Leaves initiated with an Overweight at Cantor Fitzgerald
CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

12/30/22 Cantor Fitzgerald
Curaleaf price target lowered to $12 from $13 at Cantor Fitzgerald
12/01/22 Wedbush
Wedbush starts Curaleaf with Outperform, expects share gains
12/01/22 Wedbush
Curaleaf initiated with an Outperform at Wedbush
11/08/22 Stifel
Curaleaf price target lowered to C$8.50 from C$9.50 at Stifel
DMTTF Small Pharma
/

+

12/15/22 EF Hutton
Small Pharma initiated with a Buy at EF Hutton
10/18/22 Canaccord
Small Pharma price target lowered to C$0.75 from C$1 at Canaccord
IIPR Innovative Industrial Properties
$85.74 /

-0.64 (-0.74%)

01/24/23 BTIG
Innovative Industrial Properties price target lowered to $179 from $196 at BTIG
01/20/23 JMP Securities
Innovative Industrial Properties downgraded to Market Perform at JMP Securities
01/03/23 BTIG
WeWork named Top Pick for first half of 2023 at BTIG
11/09/22 Roth Capital
Innovative Industrial Properties price target lowered to $170 from $190 at Roth Capital
ACB Aurora Cannabis
/

+

12/28/22 Piper Sandler
Aurora Cannabis price target lowered to $1 from $2 at Piper Sandler
11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
09/21/22 Canaccord
Aurora Cannabis upgraded to Hold from Sell at Canaccord
CVSI CV Sciences
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
CTST CannTrust
/

+

CGC Canopy Growth
$2.72 /

-0.045 (-1.63%)

11/07/22 Canaccord
Canopy Growth price target raised to C$5 from C$4.25 at Canaccord
11/01/22 Bernstein
Bernstein starts Canopy Growth at Underperform, sees equity raise
11/01/22 Bernstein
Canopy Growth initiated with an Underperform at Bernstein
CRON Cronos Group
$2.41 /

-0.04 (-1.63%)

11/08/22 Canaccord
Cronos Group price target lowered to C$4.75 from C$5 at Canaccord
11/01/22 Bernstein
Cronos started with Market Perform on limited visibility at Bernstein
11/01/22 Bernstein
Cronos Group initiated with a Market Perform at Bernstein
GDNSF Goodness Growth
/

+

11/16/22 Canaccord
Goodness Growth price target lowered to C$0.85 from C$1 at Canaccord
10/14/22 Alliance Global Partners
Verano Holdings price target lowered to C$12 from C$16 at Alliance Global
05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
GTBIF Green Thumb Industries
$7.81 /

-0.08 (-1.01%)

12/01/22 Wedbush
Wedbush starts Green Thumb with Outperform, names top cannabis pick
12/01/22 Wedbush
Green Thumb Industries initiated with an Outperform at Wedbush
11/03/22 Stifel
Green Thumb Industries price target raised to C$31 from C$30.50 at Stifel
TLRY Tilray
$3.04 /

-0.055 (-1.78%)

01/10/23 MKM Partners
Tilray price target lowered to $3 from $4 at MKM Partners
01/10/23 Canaccord
Tilray price target lowered to $5 from $7 at Canaccord
01/09/23 Alliance Global Partners
Tilray price target lowered to $3 from $4 at Alliance Global Partners
12/28/22 Piper Sandler
Tilray estimates lowered on softer beer sales at Piper Sandler
CANN Trees Corporation
/

+

TCNNF Trulieve Cannabis
$6.31 /

-0.35 (-5.26%)

12/01/22 Wedbush
Wedbush starts Trulieve with Outperform on broadening reach
12/01/22 Wedbush
Trulieve Cannabis initiated with an Outperform at Wedbush
11/10/22 Canaccord
Trulieve Cannabis price target lowered to C$50 from C$54 at Canaccord
ZYNE Zynerba
/

+

06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
ATAI Atai Life Sciences
$1.85 /

-0.015 (-0.80%)

01/19/23 H.C. Wainwright
Atai Life Sciences price target lowered to $20 from $50 at H.C. Wainwright
01/09/23 Canaccord
Atai Life Sciences price target lowered to $11 from $27 at Canaccord
01/09/23 Loop Capital
Atai Life Sciences price target lowered to $10 from $18 at Loop Capital
01/09/23 Citi
Atai Life Sciences price target lowered to $10 from $20 at Citi
RLMD Relmada Therapeutics
$4.31 /

-0.06 (-1.37%)

12/08/22 Truist
Relmada Therapeutics price target lowered to $4 from $7 at Truist
11/11/22 SVB Securities
Relmada 'still has a chance' for positive depression data, says SVB
10/14/22 BofA
Axsome shares could react positively to Relmada trial failure, says BofA
10/14/22 Goldman Sachs
Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs
CMPS Compass Pathways
$10.73 /

+0.12 (+1.13%)

12/15/22 EF Hutton
Compass Pathways initiated with a Buy at EF Hutton
12/09/22 Oppenheimer
Compass Pathways price target lowered to $33 from $55 at Oppenheimer
11/01/22 Loop Capital
Compass Pathways initiated with a Buy at Loop Capital
IGC India Globalization Capital
/

+

ZYNE Zynerba
/

+

TLRY Tilray
$3.04 /

-0.055 (-1.78%)

RLMD Relmada Therapeutics
$4.31 /

-0.06 (-1.37%)

IIPR Innovative Industrial Properties
$85.74 /

-0.64 (-0.74%)

CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

CRON Cronos Group
$2.41 /

-0.04 (-1.63%)

CMPS Compass Pathways
$10.73 /

+0.12 (+1.13%)

CLVR Clever Leaves
/

+

CGC Canopy Growth
$2.72 /

-0.045 (-1.63%)

ATAI Atai Life Sciences
$1.85 /

-0.015 (-0.80%)

ACB Aurora Cannabis
/

+

  • 27
    May
  • 01
    Apr
ATAI Atai Life Sciences
$1.85 /

-0.015 (-0.80%)

ACB Aurora Cannabis
/

+

LOVFF Cannara Biotech
/

+

IIPR Innovative Industrial Properties
$85.74 /

-0.64 (-0.74%)

CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

CLVR Clever Leaves
/

+

AVTBF Avant Brands
/

+

ATAI Atai Life Sciences
$1.85 /

-0.015 (-0.80%)

ACB Aurora Cannabis
/

+

TLRY Tilray
$3.04 /

-0.055 (-1.78%)

RLMD Relmada Therapeutics
$4.31 /

-0.06 (-1.37%)

IIPR Innovative Industrial Properties
$85.74 /

-0.64 (-0.74%)

CGC Canopy Growth
$2.72 /

-0.045 (-1.63%)

ACB Aurora Cannabis
/

+

Hot Stocks
Curaleaf closes operations in California, Colorado and Oregon, cuts payroll 10% » 08:04
01/26/23
01/26
08:04
01/26/23
08:04
CURLF

Curaleaf

$3.61 /

-0.2276 (-5.93%)

Curaleaf announced the…

Curaleaf announced the proactive closure of the majority of its operations in California, Colorado and Oregon, beginning this month, as part of its continued effort to streamline its business. Additionally, in an effort to further optimize operations and reduce costs, the company will consolidate cultivation and processing operations in Massachusetts to a single facility in Webster, resulting in the closure of its Amesbury facility. Curaleaf expects to record non-cash restructuring and impairment charges that it will detail on its fourth quarter earnings call in March. Concurrent with these actions, the company has reduced its payroll by 10% which, when coupled with other cost savings initiatives, it expects to realize $60M in gross run-rate expense savings in 2023, exceeding its initial savings target by 50%. The company will exit production and cultivation facilities in California, Colorado and Oregon. While these states have contributed to the growth of Select and other Curaleaf wholesale brands, the company acknowledges the difficult operating environment in these investment states and will instead place a laser focus on cash generation in its core revenue-driving markets moving forward. Curaleaf began aggressive cost-cutting measures in these states in 2022 through facility closures and reductions in workforce. These adjustments were necessary for the future success and profitability of the business and were made as a result of recent legislative decisions, price compression, and lack of enforcement of the illicit market. For context, these markets contributed less than $50M in revenue to Curaleaf last year. Curaleaf expects these market closures will be immediately accretive to its adjusted EBITDA margins and positions it for robust positive free cash flow generation in excess of $125M this year as management executes on its strategic priorities.

ShowHide Related Items >><<
CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

12/30/22 Cantor Fitzgerald
Curaleaf price target lowered to $12 from $13 at Cantor Fitzgerald
12/01/22 Wedbush
Wedbush starts Curaleaf with Outperform, expects share gains
12/01/22 Wedbush
Curaleaf initiated with an Outperform at Wedbush
11/08/22 Stifel
Curaleaf price target lowered to C$8.50 from C$9.50 at Stifel
CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

CURLF Curaleaf
$3.61 /

-0.2276 (-5.93%)

Hot Stocks
Organigram receives Nasdaq listing non-compliance notification » 06:09
01/26/23
01/26
06:09
01/26/23
06:09
OGI

Organigram

/

+

Organigram received…

Organigram received notification from Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market, since the closing bid price for the company's common shares was below $1.00 for 30 consecutive trading days. The notification has no immediate effect on the listing of the company's common shares on the Nasdaq Global Select Market. The company has a period of 180 calendar days from the date of Notification, being until July 24, to regain compliance with the Minimum Bid Requirement, during which time the common shares will continue to trade on the NASDAQ Global Select Market. In the event the company does not regain compliance with the Minimum Bid Requirement by July 24, the company may be eligible for an additional period of 180 calendar days to regain compliance or may be subject to delisting. The company's common shares are also listed on the Toronto Stock Exchange and the notification does not affect the company's compliance status with such listing.

ShowHide Related Items >><<
OGI Organigram
/

+

OGI Organigram
/

+

01/13/23 Stifel
Organigram upgraded to Buy from Hold at Stifel
01/11/23 Raymond James
Organigram price target lowered to C$2 from C$3 at Raymond James
07/15/22 Stifel
Organigram price target lowered to C$1.50 from C$2.25 at Stifel
07/15/22 Alliance Global Partners
Organigram price target lowered to C$1.50 from C$2.25 at Alliance Global
OGI Organigram
/

+

OGI Organigram
/

+

OGI Organigram
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.